Clinical Trial Update: Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion [Phase 1]

View source ↗

Summary

Bristol-Myers Squibb is conducting a Phase 1 trial of MRTX1719 in MTAP-deleted solid tumors, including mesothelioma, non-small cell lung cancer, malignant perip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peripheral Nerve Sheath Tumor
• Mesothelioma
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma

Drugs mentioned

• MRTX1719

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Mesothelioma, Non Small Cell Lung Cancer | Phase 1 | Status: RECRUITING